RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.89-1.87%
Price as of Jul 20, 2026
RXRX financials
Recursion Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $74.7M | $58.8M | $43.9M | $39.7M |
| Cost of revenue | $121.0M | $45.2M | $42.6M | $48.3M |
| Gross profit | -$46.3M | $13.6M | $1.3M | -$8.6M |
| Operating expenses | $601.9M | $492.6M | $351.3M | $237.1M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M |
| EBITDA | -$559.4M | -$426.7M | -$307.6M | -$227.7M |
| Basic EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
| Diluted EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
| Balance sheet | ||||
| Cash & equivalents | $743.3M | $594.4M | $391.6M | $549.9M |
| Total assets | $1.5B | $1.4B | $653.7M | $701.3M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M |
| Stockholders’ equity | $1.1B | $1.0B | $463.4M | $485.8M |
| Total debt | $78.0M | $108.5M | $50.7M | $51.0M |
| Net debt | -$665.3M | -$485.9M | -$340.9M | -$498.9M |
| Cash flow | ||||
| Operating cash flow | -$371.8M | -$359.2M | -$287.8M | -$83.5M |
| Capital expenditure | -$6.5M | -$13.7M | -$12.0M | -$37.4M |
| Free cash flow | -$378.3M | -$372.9M | -$300.3M | -$120.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |